With 1.02 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.06 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.87 whereas the lowest price it dropped to was $1.77. The 52-week range on PGEN shows that it touched its highest point at $2.17 and its lowest point at $0.65 during that stretch. It currently has a 1-year price target of $6.33. Beta for the stock currently stands at 1.62.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PGEN was up-trending over the past week, with a rise of 2.25%, but this was down by -4.71% over a month. Three-month performance surged to 155.37% while six-month performance rose 70.09%. The stock gained 26.39% in the past year, while it has gained 62.50% so far this year. A look at the trailing 12-month EPS for PGEN yields -0.48 with Next year EPS estimates of 0.03. For the next quarter, that number is -0.08. This implies an EPS growth rate of 42.98% for this year and 109.95% for next year.
Float and Shares Shorts:
At present, 292.87 million PGEN shares are outstanding with a float of 162.39 million shares on hand for trading. On 2025-02-28, short shares totaled 21.57 million, which was 736.9999600000001 higher than short shares on 1738281600. In addition to Mr. Randal J. Kirk J.D. as the firm’s Executive Chairman, Dr. Helen Sabzevari MPH, Ph.D. serves as its President, CEO & Director.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-12-31, PGEN reported revenue of $1190000.0 and operating income of -$22737000.0. The EBITDA in the recently reported quarter was -$13374000.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PGEN since 2 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With PGEN analysts setting a high price target of 7.0 and a low target of 6.0, the average target price over the next 12 months is 6.38667. Based on these targets, PGEN could surge 284.62% to reach the target high and rise by 229.67% to reach the target low. Reaching the average price target will result in a growth of 250.92% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.43 being high and -$0.47 being low. For PGEN, this leads to a yearly average estimate of -$0.45. Based on analyst estimates, the high estimate for the next quarter is -$0.08 and the low estimate is -$0.08. The average estimate for the next quarter is thus -$0.08.
